Print Email Facebook Twitter Abobotulinumtoxina (Dysport®), onabotulinumtoxina (botox®), and incobotulinumtoxina (xeomin®) neurotoxin content and potential implications for duration of response in patients Title Abobotulinumtoxina (Dysport®), onabotulinumtoxina (botox®), and incobotulinumtoxina (xeomin®) neurotoxin content and potential implications for duration of response in patients Author Field, M. Splevins, A. Picaut, P. van der Schans, M. Langenberg, J. Noort, D. Foster, K. Publication year 2018 Abstract Botulinum neurotoxin type-A (BoNT-A) blocks the release of acetylcholine from peripheral cholinergic nerve terminals and is an important option for the treatment of disorders characterised by excessive cholinergic neuronal activity. Several BoNT-A products are currently marketed, each with unique manufacturing processes, excipients, formulation, and non-interchangeable potency units. Nevertheless, the effects of all the products are mediated by the 150 kDa BoNT-A neurotoxin. We assessed the quantity and light chain (LC) activity of BoNT-A in three commercial BoNT-A products (Dysport®; Botox®; Xeomin®). We quantified 150 kDa BoNT-A by sandwich ELISA and assessed LC activity by EndoPep assay. In both assays, we assessed the results for the commercial products against recombinant 150 kDa BoNT-A. The mean 150 kDa BoNT-A content per vial measured by ELISA was 2.69 ng/500 U vial Dysport®, 0.90 ng/100 U vial Botox®, and 0.40 ng/100 U vial Xeomin®. To present clinically relevant results, we calculated the 150 kDa BoNT-A/US Food and Drug Administration (FDA)-approved dose in adult upper limb spasticity: 5.38 ng Dysport® (1000 U; 2 × 500 U vials), 3.60 ng Botox® (400 U; 4 × 100 U vials), and 1.61 ng Xeomin® (400 U; 4 × 100 U vials). EndoPep assay showed similar LC activity among BoNT-A products. Thus, greater amounts of active neurotoxin are injected with Dysport®, at FDA-approved doses, than with other products. This fact might explain the long duration of action reported across multiple indications, which benefits patients, caregivers, clinicians, and healthcare systems. © 2018 by the authors. Licensee MDPI, Basel, Switzerland. Subject Observation, Weapon & Protection SystemsCBRN - CBRN ProtectionBotulinum toxinBoNTSpasticityDysport®AbobotulinumtoxinAGlabellarLines To reference this document use: http://resolver.tudelft.nl/uuid:2f39b1e7-d5f2-46e8-b5e8-b9d37e42259c DOI https://doi.org/10.3390/toxins10120535 TNO identifier 858042 Publisher MDPI AG, Rijswijk ISSN 2072-6651 Source Toxins, 10 (12) Article number 535 Document type article Files To receive the publication files, please send an e-mail request to TNO Library.